GlassScriptPhysician profile
Sharon Mertins
NPI 1679601595
$2,585.87
in general payments reported to CMS, 2019-2025
34 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.26 · 2022: $1,404 · 2023: $795 · 2024: $140 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.91 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $258.24 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Edwards Lifesciences Corporation | $237.76 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ucb, INC. | $201.05 | 2022 | |
| Sk Life Science, INC. | $152.54 | 2022 | |
| Amgen INC. | $138.10 | 2025 | Repatha, Otezla |
| Lilly USA, LLC | $121.25 | 2022-2023 | Mounjaro |
| Amneal Pharmaceuticals LLC | $118.35 | 2022 | |
| Genzyme Corporation | $79.81 | 2022 | |
| Acadia Pharmaceuticals INC | $78.78 | 2022 | |
| Argenx US, INC. | $75.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $60.92 | 2022 | |
| Boston Scientific Corporation | $52.43 | 2023 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $49.54 | 2022 | |
| Upsher-Smith Laboratories LLC | $48.81 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $46.25 | 2022 | |
| Grifols USA, LLC | $42.64 | 2022 | |
| Alexion Pharmaceuticals, INC. | $40.46 | 2022 | |
| Neurelis, INC. | $40.16 | 2022 | |
| Exact Sciences Corporation | $34.17 | 2023 | Cologuard Collection Kit |
| Nevro Corp. | $28.88 | 2022 | |
| Acorda Therapeutics, INC | $28.87 | 2022 | |
| Genentech USA, INC. | $28.81 | 2022 | |
| Harmony Biosciences LLC | $21.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.95 | 2021 | |
| Pfizer INC. | $20.93 | 2025 | |
| Kyowa Kirin, INC. | $19.18 | 2022 | |
| Avion Pharmaceuticals | $16.46 | 2022 | |
| Glaxosmithkline, LLC. | $16.28 | 2025 | Shingrix |
| Merck Sharp & Dohme LLC | $15.72 | 2022 | |
| Tanabe Pharma America, INC. | $14.20 | 2022 | |
| Mallinckrodt Hospital Products INC. | $13.41 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.90 | 2022 | |
| Horizon Therapeutics Plc | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Mertins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.